Biotech | November 18, 2021
Daiichi Sankyo initiates Phase 2 trial of mRNA Covid-19 vaccine in Japan
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
The interim data combines three mRNAs into one therapy injected directly into the tumour
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
At IIT Roorkee’s Vision 2047 conference, the union minister highlights BioE3 policy, rising biotech startups, and major scientific milestones
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
Subscribe To Our Newsletter & Stay Updated
